Scientists are investigating the potential of using artificial organs created from a patient’s cells to improve the accuracy of cancer treatment predictions. These miniature organs, known as organoids, are grown from the patient’s cells and can self-organize into tissue. An advanced method involves placing these organoids on a 3D structure that mimics blood flow, creating realistic lung tissue and beating heart cells.
Compared to traditional drug testing methods using flat human cells or animal testing, these organ chips offer a more comprehensive understanding of cancer growth and human functions, aiding in the prediction of effective pharmaceuticals. Researchers at Montreal’s McGill University and Boston’s Harvard University have successfully developed personalized organ chips for patients with esophageal adenocarcinoma, a cancer with a high mortality rate.
The organ chips replicate a patient’s tumor and surrounding tissues, allowing researchers to test treatment responses. According to Lorenzo Ferri, a surgeon at McGill University Health Centre, the organ chips can identify effective drugs within four to six weeks, aligning with patients’ treatment timelines. Initial results showed that the treatment killed cancer cells in some chips while others survived, correlating with patient responses to chemotherapy.
Organoids and organ chips offer personalized treatment options by mimicking the complexity of human organs and disease conditions. This technology, developed by Harvard’s Wyss Institute, includes channels for different cell types and fluid simulating blood and tissue, providing a more accurate representation of cellular behavior compared to traditional lab tests.
The shift towards using organoids and organ chips in research aims to reduce the reliance on animal testing and accelerate drug discovery. Initiatives in the U.S. and Canada focus on developing standardized organoid models to enhance disease modeling and drug testing. Researchers anticipate that this technology will revolutionize drug development processes, offering tailored treatments based on individual genetic makeup.
Despite the potential benefits of organ chips, cost and scalability remain challenges. While the technology currently incurs expenses of up to $30,000 per patient sample, advancements like automated organoid growth could reduce costs in the future. Ethical considerations and the welfare of animals in research are also key factors to address as the field progresses towards more sustainable and effective medical research practices.
